Cite
1O Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial.
MLA
Saura, C., et al. “1O Neratinib + Capecitabine vs Lapatinib + Capecitabine in HER2+ Metastatic Breast Cancer Previously Treated with ≥2 HER2-Directed Regimens: Exploratory Biomarker Analyses from Phase III NALA Trial.” Annals of Oncology, vol. 31, May 2020, p. S15. EBSCOhost, https://doi.org/10.1016/j.annonc.2020.03.137.
APA
Saura, C., Vivancos, A., Matito, J., Wildiers, H., Brufsky, A. M., Oliveira, M., Waters, S., Hurvitz, S. A., Moy, B., Kim, S.-B., Gradishar, W. J., Queiroz, G. S., Cronemberger, E., Bebchuk, J., Keyvanjah, K., Lalani, A. S., Eli, L. D., & Delaloge, S. (2020). 1O Neratinib + capecitabine vs lapatinib + capecitabine in HER2+ metastatic breast cancer previously treated with ≥2 HER2-directed regimens: Exploratory biomarker analyses from phase III NALA trial. Annals of Oncology, 31, S15. https://doi.org/10.1016/j.annonc.2020.03.137
Chicago
Saura, C., A. Vivancos, J. Matito, H. Wildiers, A.M. Brufsky, M. Oliveira, S. Waters, et al. 2020. “1O Neratinib + Capecitabine vs Lapatinib + Capecitabine in HER2+ Metastatic Breast Cancer Previously Treated with ≥2 HER2-Directed Regimens: Exploratory Biomarker Analyses from Phase III NALA Trial.” Annals of Oncology 31 (May): S15. doi:10.1016/j.annonc.2020.03.137.